Aimabs is a biopharmaceutical company built to bridge global innovation and patient access. We partner across borders to advance and deliver transformative medicines, bringing high-impact therapies to patients with greater speed, clarity, and confidence.

With deep roots in targeted monoclonal antibody innovation, Aimabs has expanded into multiple therapeutic modalities and integrates advanced AI-enabled approaches to streamline development. Our primary focus areas include hematology, oncology, and other specialty indications with significant unmet medical need.

What sets Aimabs apart is our integrated, end-to-end capability across regulatory strategy, clinical development, and commercialization, supported by bidirectional global-local execution that connects scientific innovation to real-world clinical impact.